Literature DB >> 10421272

Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee.

H Shimada1, I M Ambros, L P Dehner, J Hata, V V Joshi, B Roald.   

Abstract

BACKGROUND: As part of the international cooperative effort to develop a complete set of International Neuroblastoma Risk Groups, the International Neuroblastoma Pathology Committee (INPC) initiated activities in 1994 to devise a morphologic classification of neuroblastic tumors (NTs; neuroblastoma, ganglioneuroblastoma, and ganglioneuroma).
METHODS: Six member pathologists (H.S., I.M.A., L.P.D., J.H., V.V.J., and B.R.) discussed and defined morphologically based classifications (Shimada classification; risk group and modified risk group proposed by Joshi et al.) on the basis of a review of 227 cases, using various pathologic characteristics of the NTs. The classification-grading system was evaluated for prognostic significance and biologic relevance.
RESULTS: The INPC has adopted a prognostic system modeled on one proposed by Shimada et al. It is an age-linked classification dependent on the differentiation grade of the neuroblasts, their cellular turnover index, and the presence or absence of Schwannian stromal development. Based on morphologic criteria defined in this article, NTs were classified into four categories and their subtypes: 1) neuroblastoma (Schwannian stroma-poor), undifferentiated, poorly differentiated, and differentiating; 2) ganglioneuroblastoma, intermixed (Schwannian stroma-rich); 3) ganglioneuroma (Schwannian stroma-dominant), maturing and mature; and 4) ganglioneuroblastoma, nodular (composite Schwannian stroma-richlstroma-dominant and stroma-poor). Specific features, such as the mitosis-karyorrhexis index, the mitotic rate, and calcification, were also included to allow the prognostic significance of the classification to be tested. Recommendations are made regarding the surgical materials to use for an optimal pathobiologic assessment and the practical handling of samples.
CONCLUSIONS: The current article covers the essentials and important points regarding the histopathologic evaluation of NTs. Using the morphologic criteria described herein, the INPC is proposing the International Neuroblastoma Pathology Classification. It is reported in a companion article in this issue (Cancer 1999;86:363-71).

Entities:  

Mesh:

Year:  1999        PMID: 10421272

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  155 in total

1.  Calreticulin mediates nerve growth factor-induced neuronal differentiation.

Authors:  Yu-Yin Shih; Akira Nakagawara; Hsinyu Lee; Hsueh-Fen Juan; Yung-Ming Jeng; Dong-Tsamn Lin; Yung-Li Yang; Yeou-Guang Tsay; Min-Chuan Huang; Chien-Yuan Pan; Wen-Ming Hsu; Yung-Feng Liao
Journal:  J Mol Neurosci       Date:  2011-12-07       Impact factor: 3.444

2.  Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.

Authors:  Rie Suganuma; Larry L Wang; Hideki Sano; Arlene Naranjo; Wendy B London; Robert C Seeger; Michael D Hogarty; Julie M Gastier-Foster; A Thomas Look; Julie R Park; John M Maris; Susan L Cohn; Gabriele Amann; Klaus Beiske; Catherine J Cullinane; Emanuele S G d'Amore; Claudio Gambini; Jason A Jarzembowski; Vijay V Joshi; Samuel Navarro; Michel Peuchmaur; Hiroyuki Shimada
Journal:  Pediatr Blood Cancer       Date:  2012-06-28       Impact factor: 3.167

3.  Exploring new frontiers in molecular imaging: Emergence of Ga PET/CT.

Authors:  Eik Hock Tan; Soon Whatt Goh
Journal:  World J Radiol       Date:  2010-02-28

4.  Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.

Authors:  Kieuhoa T Vo; Katherine K Matthay; John Neuhaus; Wendy B London; Barbara Hero; Peter F Ambros; Akira Nakagawara; Doug Miniati; Kate Wheeler; Andrew D J Pearson; Susan L Cohn; Steven G DuBois
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

5.  High levels of polo-like kinase 1 and phosphorylated translationally controlled tumor protein indicate poor prognosis in neuroblastomas.

Authors:  Pramila Ramani; Rachel Nash; Emile Sowa-Avugrah; Chris Rogers
Journal:  J Neurooncol       Date:  2015-08-29       Impact factor: 4.130

6.  Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry.

Authors:  Octavio Burgues; Samuel Navarro; Rosa Noguera; Antonio Pellín; Amparo Ruiz; Victoria Castel; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2006-08-29       Impact factor: 4.064

7.  Paraneoplastic cerebellar ataxia associated with anti-Hu antibodies and benign ganglioneuroma.

Authors:  Roberto Fancellu; Elena Corsini; Giorgio Bernardi; Paolo Buzzo; Maria Luisa Ferrari; Eleonora Lamantea; Alberto Garaventa; Mauro Truini; Sandro Salvarani
Journal:  Funct Neurol       Date:  2014 Oct-Dec

8.  Neuroblastoma in adolescents: genetic and clinical characterisation.

Authors:  Victoria Castel; Eva Villamón; Adela Cañete; Samuel Navarro; Amparo Ruiz; Carmen Melero; Antonio Herrero; Yania Yáñez; Rosa Noguera
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

9.  Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth.

Authors:  Erik H Knelson; Angela L Gaviglio; Jasmine C Nee; Mark D Starr; Andrew B Nixon; Stephen G Marcus; Gerard C Blobe
Journal:  J Clin Invest       Date:  2014-06-17       Impact factor: 14.808

10.  Triptolide-mediated cell death in neuroblastoma occurs by both apoptosis and autophagy pathways and results in inhibition of nuclear factor-kappa B activity.

Authors:  Tara C K Krosch; Veena Sangwan; Sulagna Banerjee; Nameeta Mujumdar; Vikas Dudeja; Ashok K Saluja; Selwyn M Vickers
Journal:  Am J Surg       Date:  2013-02-19       Impact factor: 2.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.